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Abstract 
Rift Valley fever virus (RVFV), a member of the Bunyaviridae family, is a mosquito-borne 
zoonotic pathogen that causes serious morbidity and mortality in livestock and humans. The 
recent spread of the virus beyond its traditional endemic boundaries in Africa to the Arabian 
Peninsula coupled with the presence of susceptible vectors in non-endemic countries has 
created increased interest in RVF vaccines. Subunit vaccines composed of specific virus 
proteins expressed in eukaryotic or prokaryotic expression systems are shown to elicit 
neutralizing antibodies in susceptible hosts. RVFV structural proteins, N-terminus glycoprotein 
(Gn) and C-terminus glycoprotein (Gc), were expressed using a recombinant baculovirus 
expression system. The recombinant proteins were reconstituted as GnGc subunit vaccine 
formulation and evaluated for immunogenicity in a target species, sheep. Six sheep were each 
immunized with a primary dose of 50 µg of each vaccine immunogen adjuvanted with 
montanide ISA25, and at day 21 post-vaccination, each animal received a second dose of the 
same vaccine. The vaccine induced strong antibody response in all animals as determined by 
indirect enzyme-linked immunosorbent assay (ELISA). Plaque reduction neutralization test 
(PRNT80) showed the primary dose of the vaccine was sufficient to elicit potentially protective 
virus neutralizing antibody titers ranging from 40 to 160, and the second vaccine dose boosted 
the titer to more than 1,280. Further, all animals tested positive for neutralizing antibodies at day 
328 pv. ELISA analysis using the recombinant nucleocapsid protein as a negative marker 
antigen indicated that the vaccine candidate is DIVA (differentiating infected from vaccinated 
animals) compatible, and represents a promising vaccine platform for RVFV infection in 
susceptible species. 
 
 Key words: Rift Valley fever virus, glycoproteins, subunit vaccine, neutralizing antibodies, 
sheep 
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Introduction 
Rift Valley fever virus (RVFV) is a mosquito-borne zoonotic pathogen that causes high morbidity 
and mortality in both livestock and humans. The virus has caused outbreaks in ruminants and 
humans in Africa and the Arabian Peninsula (Flick and Bouloy 2005) and represents a threat to 
the wellbeing and livelihood of resource-poor farmers in much of Africa (Smith, et al. 2013). It is 
classified as a select agent and risk group-3 pathogen by the Centers for Disease Control and 
Prevention (CDC) and the United States Department of Agriculture (USDA). In ruminant 
livestock, Rift Valley fever (RVF) is characterized by high mortality in young animals, notably in 
lambs, fetal malformations and widespread abortion storms; sheep are the most susceptible, 
with neonatal mortalities approaching 100% (Swanepoel and Coetzer 1994). Human infections 
are often characterized by benign fever but in small proportion of individuals could lead to more 
serious complications such as retinitis, encephalitis, neurological disorders, hepatic necrosis, or 
fatal hemorrhagic fever (Bird, et al. 2009). Although human fatal hemorrhagic cases have been 
historically estimated at 2% in infected individuals, case fatalities of up to 20% have been 
reported (Bird, et al. 2009) including the recent outbreak in Mauritania (Heald 2012). The reason 
or factors contributing to this increase in fatalities are unknown. 
 
RVFV belongs to the genus Phlebovirus within the family Bunyaviridae, which includes over 350 
named isolates (Walter and Barr 2011). It has a tripartite single-stranded RNA genome of 
negative polarity consisting of small (S), medium (M) and large (L) RNA segments. The M 
segment encodes the two structural glycoproteins, Gn/Gc, the 78-kDa protein and the non-
structural protein, NSm, whereas the S segment encodes the nucleocapsid protein (N) protein 
and the non-structural protein, NSs. The L-segment encodes  the RNA-dependent RNA 
polymerase (Elliott 1996). The N and L proteins are required for viral RNA synthesis; and the 
NSs protein, the major virulence factor, has been shown to inhibit host transcriptional immune 
response (Bouloy, et al. 2001) through generalized transcription downregulation including 
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repression of IFN-β (Billecocq, et al. 2004,Le May, et al. 2004,Le May, et al. 2008) and 
degradation of protein kinase R (Habjan, et al. 2009,Ikegami, et al. 2009). The NSm protein 
functions to suppress virus-induced apoptosis (Won, et al. 2007) and there is evidence that it 
plays a functional role in the vector competence of mosquitos for RVFV at the level of the 
midgut barrier (Kading, et al. 2014). The glycoproteins, Gn and Gc, are surface proteins that 
play a role in virus attachment to initiate infection and have been shown to carry epitopes that 
elicit the production of neutralizing antibodies, a correlate of protective immunity (Besselaar and 
Blackburn 1992,Besselaar and Blackburn 1994,Besselaar, et al. 1991).  
 
There are currently no RVFV vaccines fully approved for commercial use outside its endemic 
area in Africa and the Arabian Peninsula. Given the potential for viral spread elsewhere 
including the mainland US, there is an urgent need for a safe and efficacious vaccine. Attributes 
essential for a vaccine for use in non-endemic areas include safety and the ability to generate a 
rapid (with primary vaccination) protective immune response in a susceptible host. In endemic 
regions, RVFV in livestock has been controlled traditionally by using live-attenuated Smithburn 
strain or inactivated whole virus (Grobbelaar, et al. 2011). The Smithburn vaccine is highly 
immunogenic but is teratogenic in pregnant sheep and cattle (Botros, et al. 2006,Coetzer and 
Barnard 1977). The formalin inactivated whole-virus vaccines are safe but less immunogenic 
(Lubroth, et al. 2007). Clone 13, another live attenuated natural mutant, is now in commercial 
use in South Africa for the control of the disease in livestock (Muller, et al. 1995,Dungu, et al. 
2010). MP12, a chemically attenuated virus derived from ZH548, an Egyptian wild-type isolate 
(Caplen, et al. 1985,Vialat, et al. 1997) is being evaluated as a potential vaccine for human and 
veterinary use. The immunogenicity and pathogenicity of these latter two candidate vaccines 
have been evaluated in various animal species (Muller, et al. 1995,Morrill, et al. 1997) and 
although both vaccine candidates showed promising results, the MP12 was reported to induce 
fetal malformations during the first trimester (Hunter, et al. 2002); however a recent study 
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reported the absence of fetal malformation in pregnant ewes inoculated with the virus (Morrill, et 
al. 2013). Strategies to develop RVFV vaccines include subunit (Mandell, et al. 2010,Naslund, 
et al. 2009,Schmaljohn, et al. 1989), DNA (Lagerqvist, et al. 2009,Spik, et al. 2006), virus-like 
particles (VLPs) (Naslund, et al. 2009,de Boer, et al. 2010,Kortekaas, et al. 2012), virus replicon 
particles (Dodd, et al. 2012,Kortekaas, et al. 2011,Oreshkova, et al. 2013), virus-vectored 
(Heise, et al. 2009,Wallace, et al. 2006), modified live vaccines, developed from recombinant 
viruses engineered using reverse genetics  (Bird, et al. 2008,Bird, et al. 2011,Billecocq, et al. 
2008,Habjan, et al. 2008,Ikegami, et al. 2006), live attenuated (Muller, et al. 1995,Dungu, et al. 
2010,Caplen, et al. 1985,Morrill, et al. 2013,Smithburn 1949,Pittman 2012) and inactivated 
whole virus vaccines (Pittman, et al. 2000).  Although subunit vaccines for RVFV are generally 
considered safe and recently some progress has been made in their development, evaluation of 
immunogenicity and/or efficacy in a target species, sheep, has been performed for a few 
candidates (Kortekaas, et al. 2012,Oreshkova, et al. 2013).   On the other hand, production of 
live-vaccines requires high level of biosafety; and their use is associated with potential risk to 
personnel and reversion to virulence in vaccinated hosts. Therefore, the general availability of a 
safe, efficacious vaccine with DIVA compatibility will be extremely valuable to endemic and non-
endemic countries outside Africa.   
 
In this study, we describe the expression of the RVFV structural glycoproteins, Gn and Gc, and 
assess their immunogenicity in a natural target species, sheep. The results demonstrate the 
induction of a strong virus neutralizing antibody response with potentially protective titers 
induced within two weeks after the primary vaccination without any noticeable adverse 
reactions. Taken together, the findings suggest that a baculovirus-expressed RVFV glycoprotein 
subunit vaccine could be a potential viable candidate for development of an effective vaccine 
against RVFV.    
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MATERIALS AND METHODS 
 
Cell cultures 
The African green monkey cells, Vero E6 (ATCC, Manassas, VA), were maintained in Eagle’s 
minimal essential medium (Corning Cellgro, Manassas, VA) supplemented with 10% fetal 
bovine serum, L-glutamine and penicillin-streptomycin (Invitrogen-Life Technologies, Carlsbad, 
CA). The cultures were maintained at 37oC in humidified 5% CO2 atmosphere. The Spodoptera 
frugiperda (Sf9) cells (Invitrogen-Life Technologies) were maintained in SFM 900 II medium 
supplemented with 10% fetal bovine serum and penicillin-streptomycin (Invitrogen-Life 
Technologies). These cells were maintained at 27oC.  
 
Construction of recombinant bacmid 
The cloning and construction of recombinant bacmid was carried out as described previously 
(Faburay, et al. 2013). Briefly, the coding sequences of the RVFV structural proteins, Gn and 
Gc, were retrieved from the RVFV ZH548 isolate sequences (GenBank Accession No. 
DQ380151) and the sequences were synthesized (Genewiz, San Diego, CA) with molecular 
modifications. For Gn, the transmembrane domain and cytoplasmic tail were deleted from the 
coding sequence, and designated as Gn ectodomain (Gne) (Figure 1a). To ensure  
translocation  of both Gne and Gc into the endoplasmic reticulum (ER) and processed through 
the cellular glycosylation pathway, a specific 54-nucleotide signal peptide (SP) sequence was 
identified in the M segment of the RVFV genome as described previously (Faburay, et al. 2013); 
sequences are available on request. This SP sequence was fused to the 5’ end of the Gne and 
Gc sequences (Figure 1b). The signal peptide contained a cleavage site and cleavage is 
catalyzed by signal peptidases located in the lumen of the ER, a site for protein translation and 
posttranslational modification. The nucleoprotein (N) nucleotide sequence was amplified by 
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PCR from pET30 Ek/LIC recombinant plasmid, a gift from Dr. Friedeman Weber, University of 
Marburg, Germany, which contained the entire coding region of the S segment of the RVFV 
strain ZH548. The RVFV-specific sequences were cloned into pFastBac/CT-TOPO vector 
(Invitrogen-Life Technologies) in-frame with C-terminal polyhistidine-tagged protein resulting in 
donor plasmids, pRF-Gne, pRF-Gc and pRF-N. The individual donor plasmids were transformed 
into MAX Efficiency DH10Bac competent E. coli to generate recombinant bacmids. 
Recombinant bacmids were purified and used for transfection to express the respective 
proteins. 
 
Recombinant baculovirus expression and purification of RVFV proteins 
Recombinant baculovirus expression of the respective RVFV proteins was carried out as 
described previously (Faburay, et al. 2013). Briefly, purified recombinant bacmids carrying the 
respective coding sequences (Gne, Gc and N) of RVFV were transfected, using CellfectinII 
reagent (Invitrogen-Life Technologies), into Sf9 cells (Invitrogen-Life Technologies) grown in Sf-
900 II SFM medium (Invitrogen-Life Technologies) supplemented with 10% fetal bovine serum 
and 100U/ml-100 µg/ml penicillin-streptomycin. Protein expression was carried out using P2 or 
higher passage recombinant baculovirus stock (>107 pfu/ml). Western blot analysis of the lysate 
was performed to confirm specific protein expression as described below. The proteins were 
expressed with a C-terminal 6xHis-tag and purification  using Ni-NTA superflow resin (Novagen, 
Rockland, MA) was performed according to the protocol described previously (Faburay, et al. 
2013). The purified proteins were stained with Coomassie Blue, and protein concentrations 
were determined using the bicinchoninic acid (BCA) assay (Thermo Scientific, Rockford, IL) at 
an absorbance of 562 nm, using bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, Mo) as 
the protein standard. Aliquots were stored at – 80oC until used.  
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Expression and purification of RVFV N protein 
Recombinant E. coli expression of RVFV N protein was carried out using an expression 
construct kindly provided by Dr. Friedeman Weber, University of Marburg, Germany. The E. coli 
cells Bl21(DE3)pRARE harboring the expression vector pCDNA3.1 were grown on Luria Bertani 
(LB) agar plates containing 100 μg/ml ampicillin and 34 μg/ml chloramphenicol.  A single clone 
was picked and inoculated into 10 ml LB media for overnight growth. Ten milliliters of the 
overnight culture was then inoculated into 1 liter of LB medium, and expression was induced 
with the addition of 0.4 mM IPTG when OD600 reached 0.6. The culture was grown overnight at 
15°C. Cells were harvested by centrifugation at 4,500 x g for 15 min at 4°C, resuspended in 1 
ml lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl) and lysed by three freeze-thaw cycles 
and then sonicated three times for 5 sec each  (Sonic Dismembrator, Model 100, Fischer 
Scientific, Inc.) . The lysate was fractionated by centrifugation for 30 min at 10,000 x g. The 
supernatant was clarified through 0.45 µm filter and then loaded onto a 5 ml HisTrap HP column 
(GE HealthCare) in conjunction with an AKTA Xpress purification system at flow rate of 1 ml 
/min. The columns were washed with Buffer A (50 mM Tris, 300 mM NaCl, pH=8.0) over 10 
column volumes. Non-specifically bound proteins were removed by washing with 5 column 
volumes of 10% Buffer B (50 mM Tris, 300 mM NaCl, pH=8.0, 500 mM imidazole). Protein was 
eluted from the column with a gradient of 10-100% Buffer B over 10 column volumes. The 
elution fractions, which contained the purified N protein were pooled and stored at -800C after 
addition of equal volume of 100% glycerol. 
 
Detection of recombinant protein expression and analysis of immunoreactivity 
The procedure for detection of recombinant protein expression by Western blot has been 
described previously (Faburay, et al. 2013). Expression of recombinant proteins, N and Gne,  
was  further confirmed using  primary antibodies, mouse anti-N (R3-ID8) and mouse anti-Gn 
monoclonal antibody, 4D4, (a gift from Dr. Connie Schmaljohn, United States Army Medical 
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Research Institute for Infectious Diseases), respectively at a dilution of 1:2,000. To probe 
immunoreactivity of antisera obtained from sheep vaccinated with recombinant RVFV Gne and 
Gc glycoprotein subunit vaccine, the blots were incubated with individual sheep sera at 1:100 
dilution for 1hr at room temperature. After washing, the membrane was incubated for 1 hr at 
room temperature with Protein G-HRP (Abcam, Cambridge, MA) diluted 1: 25,000. After the 
final washing steps, specific reactivity was detected using AEC (3-Amino-9-ethyl-carbazole) 
peroxidase substrate (Sigma-Aldrich, St. Louis, MO) or ECL enhanced chemiluminescent 
detection system. 
 
Preparation of the vaccine, animal immunization and MP12 virus antiserum 
The purified glycoproteins were formulated in montanide ISA25 water-in-oil adjuvant (Seppic, 
France) to obtain a concentration of 50 µg of each immunogen per vaccine dose according to 
the manufacturer’s instruction. Six adult sheep (#9, #36, #163, #169, #170, #179), Rambouillet 
breed, were each immunized subcutaneously with a primary dose of 50 µg of purified Gne and 
50 µg of purified Gc. At day 21 post-primary vaccination, hereafter referred to simply as 
postvaccination (pv), each sheep was given a booster with the same amount of vaccine (a 
second dose). At different time points after vaccination, the injection sites were inspected for 
possible adverse reaction. Blood samples were collected from the jugular vein of each sheep for 
the separation of sera prior to vaccination (day 0), in order to establish baseline pre-vaccination 
immune response status. Thereafter, serum samples were collected from each sheep weekly on 
days 7, 14, 21, 28, 35, 42 and 49 pv. All sera were stored at -80oC until used. The RVFV MP12 
control antiserum was obtained from a sheep at day 28 postinfection in a previous experiment 
conducted at the Kansas State University Biosecurity Research Institute (BRI) (Faburay, et al. 
2013). Animal experiments complied with institutional guidelines of South Dakota State 
University and were approved (Committee Approval No. 12-037A) by South Dakota State 
University Institutional Animal Care and Use Committee (IACUC). 
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Immunogen-specific antibody response  
Specific antibody response in serum was measured by enzyme-linked immunosorbent assay 
(ELISA) using nickel column-purified baculovirus-expressed RVFV Gne, Gc and E. coli-
expressed RVFV N proteins. The N protein was expressed in E. coil using an expression 
construct kindly provided by Friedeman Weber, University of Marburg. Germany, and was used 
as a negative diagnostic marker antigen to assess the DIVA compatibility of the recombinant 
subunit vaccine. To perform an ELISA, each well, in a 96-well plate (Nunc, Maxisorp) format, 
was coated overnight at 4oC with approximately 100 ng of each purified recombinant protein in 
100 µl of Dulbecco’s coating buffer (pH 7.4) (Invitrogen-Life Technologies).  The ELISA assays 
were performed as described previously (Faburay, et al. 2013). The cut-off point was 
determined for each sheep in each specific ELISA by the addition of two standard deviations to 
the corresponding mean OD value of the pre-vaccination serum. Mean OD values equal to or 
greater than the cut-off value were considered positive. 
 
Anti-RVF virus PRNT80  
The stock of MP12 RVFV was diluted to 50 PFU in 250 µl of 1x MEM containing 4% bovine 
serum albumin (Sigma-Aldrich, St. Louis, MO). Separately, aliquots of serum from each 
vaccinated sheep were diluted as follows: 1:10, 1:20, 1:40, 1:80, 1:160, 1:320, 1:640, and 
1:1280 in 1x MEM containing 2% bovine serum albumin and 1% penicillin streptomycin. Diluted 
serum (250 µl) was mixed with an equal volume of diluted MP12 virus and incubated at 37oC for 
1 hr. Thereafter, each mixture of serum plus RVFV was used to infect confluent monolayers of 
Vero E6 cells in 12-well plates. After 1 hr adsorption at 37oC and 5% CO2, the mixture was 
removed, and 1.5 ml of nutrient agarose overlay (1x MEM, 4% bovine serum albumin, and 0.9% 
SeaPlaque agar) was added to the monolayers. After 5 days incubation, the cells were fixed 
with 10% neutral buffered formalin for 3 hrs prior to removal of the agarose overlay.  The 
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monolayer was stained with 0.5% crystal violet in PBS, and plaques were enumerated. The 
calculated PRNT80 corresponded to the reciprocal titer of the highest serum dilution, which 
reduced the number of plaques by 80% or more relative to the virus control. As positive 
neutralizing serum control, a 1:40 dilution of day 28 serum obtained from a sheep previously 
immunized with RVFV GnGc VLP was used. The serum showed a PRNT80 titer of 1,280 (data 
not shown). Studies in humans and non-human primates show that a PRNT80 titer of ≥40 is 
protective against virulent RVFV challenge (Pittman, et al. 2000,Papin, et al. 2011); thus in this 
study a PRNT80 titer of ≥40 was considered potentially protective.   
 
Electron microscopy 
Co-expression of RVFV glycoproteins, Gne and Gc, in cell culture has been shown to result in 
the formation of VLPs (Mandell, et al. 2010, de Boer, et al. 2010). Thus to rule out possibility of 
assembly of recombinant Gne and Gc upon mixing of the proteins into vaccine formulation, a 
transmission electron microscopy (TEM) was performed. Briefly, equal amounts of purified Gne 
and Gc were mixed together in a single tube and incubated for 30 min at room temperature. 
Alongside, aliquots of purified Gne and Gc were also made in separate tubes and incubated for 
30 min as described above as controls. Subsequently, the proteins were nebulized on cupper 
Formar-carbon coated grids (Tedd Pella Inc., Redding, CA), dried at room temperature for 30 
min and stained with phosphotungstic acid (PTA). Images were recorded at a calibrated 
magnification of 30,000x or 60,000x using an electron microscope (FEI Technai G2 Spirit biot, 
Hillsboro, Ore). 
 
Statistical analysis  
We used a t-test of independent samples with equal or unequal variances for statistical analysis. 
To determine the significance of observed differences in the optical density (OD) values of 
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prevaccination and postvaccination sera, a serum reactivity index (SRI) for each sheep,  defined 
as the ratio of postvaccination serum OD value to the prevaccination serum OD value, was 
determined.  
 
Results  
Expression of RVFV N, Gn and Gc recombinant proteins 
Recombinant baculovirus expression of the target proteins was analyzed by SDS-PAGE and 
Western blot. Using anti-hisHRP monoclonal antibody, expression of recombinant N, Gne and 
Gc glycoproteins of RVFV was detected. The expression of the recombinant proteins is a 
continuation of our previous work on the expression of RVFV structural and non-structural 
proteins, which confirmed the expression of Gne and Gc in glycosylated form. A ~31 kDa N 
protein, ~52 kDa Gne protein and a ~60 kDa Gc protein were detected (Faburay, et al. 2013). 
Expression of N protein and Gne glycoprotein was confirmed using mouse anti-N  and anti-Gn 
monoclonal antibodies, respectively (Faburay, et al. 2013) . Reactivity of recombinant Gc was 
confirmed in Western blot using antisera obtained from RVFV-infected sheep (Faburay, et al. 
2013). A Coomassie blue stain of purified Gne and Gc used as vaccine immunogens and in 
ELISA showed significant enrichment  of the recombinant proteins with  a substantial amount of 
the purified total protein (estimated at ≥ 80%) consisting of the target protein (Figure 1c). 
Additional Western blot analysis showed specific immunoreactivity of recombinant Gne and Gc 
with day 28 pv sheep sera, whereas recombinant N protein showed no specific reactivity (data 
not shown).  
 
Vaccination and Immunogenicity of Gne and Gc glycoproteins 
To examine vaccine-induced seroconversion and the kinetics of antibody response, sera 
collected from the vaccinated sheep at various time points pv (day 0, 7, 14, 21, 28, 35, 42 and 
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49), were tested in Gne and Gc-specific indirect ELISAs (Figure 2a and b). The vaccine 
immunogens, as well as antigens used in the ELISA assays, were prepared from purified 
proteins enriched for the recombinant glycoproteins  (Figure 1c). Thus it was considered that the 
overwhelming antibody responses detected in the ELISAs were vaccine-induced and highly 
specific to Gne and Gc. Antibody reactivity with Gne antigen was detected in three of the sheep 
at day 7 pv (Figure 2a). At day 14 pv, all sheep seroconverted showing reactivity in the Gne and 
Gc-specific ELISAs, with Gne-specific antibodies showing comparatively stronger early-onset 
reactivity (Figure 2a and b). A second vaccine dose at day 21 pv significantly (P < 0.05) 
increased specific reactivity with both antigens at day 28 pv (Figure 2a and b). Serum reactivity 
index (SRI), a metric for vaccine-induced antibody response in vaccinated animals, showed an 
increase in OD values ranging from 4 to 9.6 fold,  to the Gne antigen (Figure 2c) and 8 to 22.4 
fold to the Gc antigen (Figure 2d). For both antigens, peak induction of antibody response was 
observed at day 28 pv (Figure 2a and b). Inspection of the injection sites revealed no adverse 
reaction (granuloma, skin ulceration, etc.) to vaccine administration.           
 
DIVA compatibility of recombinant RVFV GnGc glycoprotein subunit vaccine  
A DIVA (the ability to differentiate naturally infected from vaccinated animals) concept analysis 
by indirect ELISA was carried out using the Gne protein, as a positive diagnostic antigen, and N 
protein, as a negative marker, to detect specific antibodies in vaccinated sheep. Using sera from 
vaccinated sheep, an increase in immunoreactivity with Gne antigen was observed from day 7 
pv to day 28 pv, which later plateaued until the end of the experiment (Figure 3a). In contrast, 
immunoreactivity with N-antigen was barely detectable, remaining at baseline levels throughout 
the experiment (Figure 3a). To confirm the specific immunoreactivity of the  N protein as a  
marker antigen in ELISA, a day-28 MP12 postinfection antiserum (positive control) was tested  
alongside sera obtained from sheep  vaccinated with the glycoprotein-based vaccine (Figure 
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3b). Reactivity with these sera remained at baseline negative levels at all the time-points, 
whereas the MP12 control serum showed strong reactivity as indicated by a high OD value (P < 
0.05). 
 
Recombinant RVFV glycoproteins elicit neutralizing antibody response 
To examine vaccine-induced neutralizing antibody response, a plaque reduction neutralization 
assay was performed using an attenuated RVFV virus strain, MP12. A representative sample of 
a negative and positive PRNT80 assay using prebled and day 28 pv sera (sheep #170), 
respectively, is shown (Figure 4a and b).  In this study, a serum neutralizing antibody titer of 40 
or greater is considered potentially protective (Pittman, et al. 2000,Papin, et al. 2011). Five of 
the six vaccinated sheep showed protective neutralizing titers at day 14 pv in response to the 
primary vaccination, with antibody titers ranging from 40 to 160, and one sheep, #9, showed 
protective neutralizing titer of 40 as early as day 7 pv (Table1). Protective levels of virus 
neutralizing titers were maintained in all the sheep until day 21 pv with three of the five sheep 
(#170, #179, #36) showing a titer increase. A second vaccine dose administered day 21 pv 
significantly boosted response in all six sheep above 1,280 titer, at day 28 pv (Figure 4c) (Table 
1). Neutralizing antibody titers remained high in all sheep until day 49 pv (Figure 4c) and all 
animals were positive for RVFV neutralizing antibodies when tested at day 328 pv with titers 
ranging from 80 to 160 (Table 1).  
  
Electron microscopy  
The purpose of transmission electron microscopy (TEM) was to rule out the formation of VLPs 
following mixing of the recombinant glycoproteins, Gne and Gc, into vaccine formulation. 
Images revealed by TEM showed clumps of protein aggregates that showed no resemblance to 
VLPs (Figure 5).  
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Discussion 
The impact of RVF outbreaks in Africa and the Arabian Peninsula, and the potential for viral 
spread to non-endemic areas, makes the development of safe and efficacious vaccines urgent. 
RVFV is a suitable candidate for a one-health focused approach to prevent both livestock and 
human disease through animal vaccinations (Oreshkova, et al. 2013). However, there are 
currently no fully licensed or commercial vaccines for human or livestock use outside endemic 
areas, despite numerous potential vaccine candidates. Essential attributes for a RVFV vaccine 
include safety and high immunogenicity, DIVA compatibility and the ability to induce a rapid 
onset of protective response with single vaccination, at most within two weeks of administration 
in susceptible host species. Herein, the immunogenicity of a recombinant baculovirus-
expressed RVFV Gne and Gc glycoprotein-based vaccine candidate in a natural host species, 
the sheep, is reported. Gn and Gc are presented as glycosylated proteins on the surface of RVF 
virions and have been shown to carry epitopes that elicit neutralizing antibodies, the only 
established correlate of protective immunity against virus infection (Besselaar and Blackburn 
1992,Besselaar, et al. 1991). They are also utilized by the virus for attachment to target cells 
(Schmaljohn and Nichol 2006). Thus the surface glycoproteins represent ideal targets for 
vaccine development; and we hypothesized that antibodies targeting epitopes on both structural 
glycoproteins in a subunit vaccine would generate a strong virus neutralizing effect. To produce 
vaccine immunogens, Gne and Gc expression constructs were designed to include a signal 
peptide at their N-terminus containing a signal peptidase cleavage site that ensures processing 
through translocation into the ER and the cellular glycosylation pathway and as well enhances 
protein expression (Faburay, et al. 2013). Subsequently, sheep were immunized with the 
purified baculovirus-expressed Gne and Gc proteins adjuvanted with montanide ISA25 resulting 
in induction of virus neutralizing antibody response, followed by a strong response after the 
booster dose,  in all vaccinated animals. However, due to lack of approval at the time of this 
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study to perform challenge experiments with wild type RVFV, it was not possible to conduct 
further studies to test the efficacy of the vaccine. The vaccine induced potentially protective, (i.e. 
1:40), virus neutralizing titers with single vaccination in five of the six animals within two weeks 
pv (Table 1). These results compared favorably with the outcome of recently reported 
vaccinations using  vaccines based on RVFV glycoproteins, such as GnGc-VLPs and Gn-
ectodomain (Mandell, et al. 2010,Naslund, et al. 2009,de Boer, et al. 2010,Kortekaas, et al. 
2012,Oreshkova, et al. 2013), as well as a Newcastle Disease virus-vectored vaccine (NDFL-
GnGc) (Kortekaas, et al. 2010,Kortekaas, et al. 2010) and virus replicon particles (Dodd, et al. 
2012,Oreshkova, et al. 2013), some of which have also been reported to elicit neutralizing 
antibodies with single vaccination in  sheep (Kortekaas, et al. 2012,Oreshkova, et al. 
2013,Kortekaas, et al. 2010).  Of significance, is that  the GnGc-based recombinant protein 
vaccine candidate tested in this study induced potentially protective neutralizing antibody titers 
with single vaccination in 80% (5/6) of sheep within two weeks of vaccination and 100 % (6/6) 
sheep at three weeks pv (Table 1).  The robust neutralizing antibody response elicited by the 
RVFV vaccine candidate could be attributed to the concurrent use of Gne and Gc proteins as 
vaccine immunogens. Gn is known to contain virus neutralizing epitopes, whereas inclusion of 
Gc in the vaccine is suggested to provide an additional target for neutralizing antibodies 
(Besselaar and Blackburn 1992,Besselaar, et al. 1991).  Neutralizing antibody titers increased 
sharply in all animals following the booster   and this high anamnestic response was maintained 
in all animals for more than three weeks, i.e., up to day 49 post vaccination. Remarkably, 
neutralizing antibody titers, ranging from 80 to 160, above the potentially protective threshold, 
was detected in all sheep at day 328 postvaccination (Table 1). This is against the backdrop 
that in the US, the withdrawal time for the adjuvant used in the current vaccine is 90 days.  An 
early-onset vaccine-induced IgG antibody response to Gne occurred in half of the sheep within 
seven days pv followed by seroconversion in 100% of the animals at two weeks pv for both Gne 
and Gc (Figure 2a, b, c and d). It is noteworthy that high ELISA background was detected in 
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some sheep. Although this is speculated to be due to a host of unknown factors including the 
physiological status of individual animals, it nonetheless indicates the need for further 
development of the assay. Taken together, these results support the conclusion that the RVFV 
recombinant GnGc glycoprotein-based vaccine candidate is highly immunogenic, eliciting strong 
immune response in sheep, the natural and most susceptible species to RVFV.  
 
Differentiating infected from vaccinated animals (DIVA) during RVF disease outbreaks is of 
fundamental epidemiological importance. Therefore, DIVA compatibility of a vaccine with 
accompanying diagnostic tests represents an important factor for consideration when designing 
vaccines especially for use in countries or regions non-endemic for RVFV. Using the RVFV 
glycoproteins and the nucleocapsid protein as diagnostic antigens, it was possible to distinguish 
vaccine-induced antibody responses (Figure 3a) from RVFV MP12 infection in sheep (Figure 
3b).  The increase in international trade in livestock coupled with the potential for RVFV 
outbreaks in non-endemic areas provides strong incentives for the development of DIVA 
vaccines. The absence of the nucleoprotein in the vaccine offers the possibility of developing a 
DIVA vaccine with a companion diagnostic assay using the recombinant N and Gne/Gc ELISA. 
The N protein represents a suitable diagnostic antigen as it is the most abundant viral protein 
and is highly immunogenic, inducing antibodies within the first days after infection (Faburay, et 
al. 2013,Swanepoel, et al. 1986,Paweska, et al. 2008).  Furthermore, the recombinant GnGc 
glycoprotein subunit vaccine candidate elicited strong neutralizing and IgG antibody responses 
in the natural host, which can be easily detected by ELISA assays; analysis of the structural 
morphology of the vaccine immunogens by electron microscopy confirmed that the proteins 
upon reconstitution formed into clumps or aggregates which were very much distinct from VLPs 
(Figure 5). To date, RVFV VLP assembly has been reported to occur only by simultaneous 
production of Gn and Gc in both mammalian (Mandell, et al. 2010,Mandell, et al. 2010) and 
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insect cells (de Boer, et al. 2010,Liu, et al. 2008) and in all cases involved the co-expression of 
nonhistidine-tagged proteins. These results are anticipated, for unlike with naked viruses, where 
VLPs are re-assembled proteins, formation of an enveloped virus such as RVFV requires live 
cells.   
 
RVFV represents a threat to human and animal health and there is no commercially available 
vaccine or effective antiviral therapeutic agent for human use. Efforts to produce live attenuated 
vaccines (Bouloy and Flick 2009) are tempered by safety concerns; however, such safety 
concerns are comparatively lower for recombinant protein-based vaccines. However, unlike live-
attenuated vaccines, recombinant protein-based vaccines generally require booster to elicit 
long-term protective immune response. Therefore future research will be directed at further 
improving the duration and onset of protective neutralizing antibody responses.  Additionally, the 
fact that RVFV has low genetic diversity and consists of a single serotype suggests that the 
recombinant Gne and Gc glycoprotein vaccine would likely confer protection against all strains 
of the virus. Further evaluation of the efficacy of the vaccine in livestock and non-human 
primates is the next step towards developing a safe and efficacious vaccine for livestock and 
human use.                                  
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Tables  
Table 1. Reciprocal PRNT80 titers in sheep in response to vaccination with RVFV recombinant GnGc glycoprotein subunit vaccine 
____________________________________________________________________________________________________________________ 
       Reciprocal PRNT80 titers 
Sheep No.  _______________________________________________________________________________________________________ 
  Days:  0 prevac   7 pv     14 pv          21 pv     28 pv     35 pv      42 pv     49 pv  328 pv 
____________________________________________________________________________________________________________________ 
     169   0     0       40             40   1280>  1280>  1280>  1280       80 
 
     163   0     0       10             20   1280>    640  1280>  1280     80 
 
     170   0     0       40             80   1280>  1280>  1280>  1280>     80 
 
     179   0     0        40             80   1280>  1280>  1280>  1280    160 
 
       9   0    40      160             80   1280>   1280>  1280  1280    160 
  
      36   0     0       80           160   1280>   1280  1280  1280      80 
 
   Mean   0    nd       62             77   1280>      nd    1280>  1280>     107 
 
  Range   0    nd   10 – 160     20 – 160   1280>          640 – 1280>       1280 – 1280>    1280 – 1280> 80 - 160 
____________________________________________________________________________________________________________________ 
prevac = prevaccination; pv = postvaccination; nd = not determinable 
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Figures 
 
 
Figure 1.  Creation of Gne and Gc recombinant  constructs and recombinant protein expression. 
(A) shows diagrammatic representation of deletion of the transmembrane (TM) domain (black 
boxes) and the cytoplasmic tail of Gn. (B) shows diagrammatic representation of signal peptide 
(SP) with a signal peptidase cleavage site (scissors) identified in the M segment of RVFV 
genome  is fused to the 5 terminus of Gne and Gc. () denotes putative glycosylation sites 
(Gerrard and Nichol 2007). (C) Coomassie blue stain of purified recombinant Gne,  Gc and 
empty baculovirus-infected, mock purified cell lysate (EBM).   M = molecular weight marker.  
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Figure 2. Analysis of vaccine-induced IgG host antibody response by antigen-specific indirect 
ELISAs, Gne-ELISA (A) and Gc-ELISA (B) depict time-dependent increase in specific antibody 
titer. Analysis of serum reactivity indices (SRI) using prebled sera against day 28 pv sera show 
significant increase in specific antibody titers (P < 0.05) demonstrated by high SRI values in 
both Gne-ELISA (C) and Gc-ELISA (D). Prevac = prevaccination serum; postvac = 
postvaccination serum; SRI = serum reactivity index. The cut-off value for individual sheep in 
Gne-ELISA: #163 = 0.354; #169 = 0.167; #170 = 0.507; #179 = 0.365; #36 = 0.252; #9 = 0.668. 
The cut-off value in Gc-ELISA: #163 = 0.215; #169 = 0.151; #170 = 0.309; #179 = 0.104; #36 = 
0.7135; #9 = 0.259. A cut-off value was determined for each sheep as described in materials 
and methods.  
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Figure 3. DiVA analysis of the subunit shows Indirect IgG ELISA  of RVFV anti-Gn and anti-N 
antibody response in the vaccinated sheep. A) Reactivity of sera with Gne antigen indicates a 
time-dependent increase in antibody response, whereas in N-ELISA, reactivity remains at 
baseline prevaccination levels at all time points for all sera obtained from the vaccinated sheep. 
B) Comparison of the reactivity of sera obtained from sheep vaccinated with the glycoprotein-
based subunit vaccine to sera obtained from RVFV MP12 infected sheep, the positive control 
serum (PC). The N antigen was positively reactive with only the positive control serum indicated 
by high mean OD value; day 0 to day 49 sera were obtained from sheep #169. The cut-off value 
for individual sheep in Gne-ELISA: #163 = 0.354; #169 = 0.167; #170 = 0.507; #179 = 0.365; 
#36 = 0.252; #9 = 0.668. The cut-off value in N-ELISA for individual sheep tested: #169N = 
0.288; #163N = 0.237; #170N = 0.212; #9N = 0.407; #179N = 0.188; #36N = 0.239. N denotes 
recombinant N antigen used in ELISA. A cut-off value was determined for each sheep as 
described in materials and methods. 
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Figure 4.  An illustration of plaque reduction neutralization test (PRNT80) shows a negative (A) 
and a positive (B) RVFV neutralization test result. Protective levels of RVFV neutralizing 
antibody titers (≥40) are detectable in the animals within 2 weeks postvaccination. A marked 
increase in RVFV neutralizing antibody titer  is detected in all animals following administration of 
the second vaccine dose (C). PC = positive control serum (1:40 dilution); VC = virus control (50 
pfu).  
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Figure 5.  Electromicrograph of purified recombinant RVFV proteins used in the vaccine 
formulation. Recombinant Gne, Gc as well as mixed  GnGc show  clumps of protein aggregates 
that are structurally distinct from RVF VLPs, shown as control (de Boer, et al. 2010). Gne and 
Gc are mixed in equal amounts and incubated at room temparture to allow possible assembly of 
proteins into VLPs. The picture illustrates the non-formation of VLPs. 
 
 
